UCB kept at neutral by Merrill

Merrill Lynch analyst Erica Whittaker maintained UCB's neutral rating after a company competitor Abbott announced that Humira has been granted priority review for its Crohn's disease approval application, which was unexpected. This means that Humira could be approved six months from its end August filing date, which would give UCB's Cimzia only a two to three month head start over Humira in the market if Cimzia is approved on its PDUFA date at end of 2006. Shares of the Brussels, Belgium-based biopharmaceutical company were unchanged at $63.25. (Brussels: UCB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.